Clinical Trials Browser

Phase 2 × rasburicase × Other hematologic neoplasm × Clear all

Leukemia, Lymphoma, Tumor Lysis Syndrome, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT01564277 2018-01-09

Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies

Congenital Abnormalities, Blast Crisis, Burkitt Lymphoma, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00628628 2013-08-01

Rasburicase in Patients at Risk for Tumor Lysis Syndrome

Phase 2 Completed

82 enrolled 6 charts

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Tumor Lysis Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hyperuricemia

NCT00631579 2009-10-02

Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma

Phase 2 Completed

50 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Hyperuricemia

NCT00290992 2009-03-30

Rasburicase for Hyperuricemia

Phase 2 Completed

30 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Nutritional and Metabolic Diseases, Hyperuricemia

Clinical Trials

Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2

Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies

Rasburicase in Patients at Risk for Tumor Lysis Syndrome

Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma

Rasburicase for Hyperuricemia